Literature DB >> 17612524

Lobelane decreases methamphetamine self-administration in rats.

Nichole M Neugebauer1, Steven B Harrod, Dustin J Stairs, Peter A Crooks, Linda P Dwoskin, Michael T Bardo.   

Abstract

Lobelane, a minor alkaloid of Lobelia inflata and a synthetic, des-oxy analog of lobeline, has good affinity for the vesicular monoamine transporter and the dopamine transporter. The current study examined the ability of lobelane to specifically decrease methamphetamine self-administration. Rats were trained on a fixed ratio 5 schedule of reinforcement to self-administer methamphetamine (0.05 mg/kg/infusion, i.v.) or to respond for sucrose pellets. Upon reaching stable responding, rats were pretreated with lobelane (0.1, 1, 3, 5.6, or 10 mg/kg, s.c.) or saline, 15 min prior to the operant session. To assess the effect of repeated lobelane on methamphetamine self-administration, rats were pretreated with lobelane (5.6 or 10 mg/kg, s.c.) for 7 sessions. Behavioral specificity was further investigated by assessing the effects of lobelane (0.1, 1, 3, 5, or 10 mg/kg, s.c.) or saline on locomotor activity. Within the dose range tested, lobelane dose-dependently decreased methamphetamine self-administration, while having no effect on sucrose-maintained responding. Locomotor activity was decreased following only the highest dose of lobelane (10 mg/kg). Across repeated pretreatments, tolerance developed to the effect of lobelane on methamphetamine self-administration, demonstrating that the ability of lobelane to specifically decrease methamphetamine self-administration is a transient effect. Thus, taken together, the results show that although lobelane interacts with the pharmacological targets believed to be responsible for its ability to decrease methamphetamine self-administration, removal of the oxygen functionalities from the lobeline molecule may have afforded a compound with an altered pharmacokinetic and/or pharmacodynamic profile.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17612524      PMCID: PMC2104779          DOI: 10.1016/j.ejphar.2007.06.003

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  17 in total

Review 1.  A novel mechanism of action and potential use for lobeline as a treatment for psychostimulant abuse.

Authors:  Linda P Dwoskin; Peter A Crooks
Journal:  Biochem Pharmacol       Date:  2002-01-15       Impact factor: 5.858

2.  Lobeline attenuates locomotor stimulation induced by repeated nicotine administration in rats.

Authors:  Dennis K Miller; Steven B Harrod; Thomas A Green; Mei-Yee Wong; Michael T Bardo; Linda P Dwoskin
Journal:  Pharmacol Biochem Behav       Date:  2003-01       Impact factor: 3.533

3.  The mGluR5 antagonist MPEP decreased nicotine self-administration in rats and mice.

Authors:  Neil E Paterson; Svetlana Semenova; Fabrizio Gasparini; Athina Markou
Journal:  Psychopharmacology (Berl)       Date:  2003-04-08       Impact factor: 4.530

4.  Lobeline attenuates d-methamphetamine self-administration in rats.

Authors:  S B Harrod; L P Dwoskin; P A Crooks; J E Klebaur; M T Bardo
Journal:  J Pharmacol Exp Ther       Date:  2001-07       Impact factor: 4.030

Review 5.  Sites, mechanisms, and structural characteristics of the brain's nicotine receptor.

Authors:  L G Abood; S Banerjee; D B Kanne
Journal:  J Subst Abuse       Date:  1989

6.  Inhibition of monoamine oxidase by d-methamphetamine.

Authors:  O Suzuki; H Hattori; M Asano; M Oya; Y Katsumata
Journal:  Biochem Pharmacol       Date:  1980-07-15       Impact factor: 5.858

7.  Behavioural and pharmacokinetic studies on nicotine, cytisine and lobeline.

Authors:  C Reavill; B Walther; I P Stolerman; B Testa
Journal:  Neuropharmacology       Date:  1990-07       Impact factor: 5.250

8.  Lobeline inhibits nicotine-evoked [(3)H]dopamine overflow from rat striatal slices and nicotine-evoked (86)Rb(+) efflux from thalamic synaptosomes.

Authors:  D K Miller; P A Crooks; L P Dwoskin
Journal:  Neuropharmacology       Date:  2000-10       Impact factor: 5.250

9.  Preclinical evaluation of GBR12909 decanoate as a long-acting medication for methamphetamine dependence.

Authors:  Michael H Baumann; Jennifer M Phillips; Mario A Ayestas; Syed F Ali; Kenner C Rice; Richard B Rothman
Journal:  Ann N Y Acad Sci       Date:  2002-06       Impact factor: 5.691

10.  Lobeline analogs with enhanced affinity and selectivity for plasmalemma and vesicular monoamine transporters.

Authors:  Dennis K Miller; Peter A Crooks; Guangrong Zheng; Vladimir P Grinevich; Seth D Norrholm; Linda P Dwoskin
Journal:  J Pharmacol Exp Ther       Date:  2004-04-30       Impact factor: 4.030

View more
  37 in total

1.  The effect of a novel VMAT2 inhibitor, GZ-793A, on methamphetamine reward in rats.

Authors:  Joshua S Beckmann; Emily D Denehy; Guangrong Zheng; Peter A Crooks; Linda P Dwoskin; Michael T Bardo
Journal:  Psychopharmacology (Berl)       Date:  2011-09-21       Impact factor: 4.530

2.  Phenyl ring-substituted lobelane analogs: inhibition of [³H]dopamine uptake at the vesicular monoamine transporter-2.

Authors:  Justin R Nickell; Guangrong Zheng; Agripina G Deaciuc; Peter A Crooks; Linda P Dwoskin
Journal:  J Pharmacol Exp Ther       Date:  2010-09-28       Impact factor: 4.030

3.  Investigating Methamphetamine Craving Using the Extinction-Reinstatement Model in the Rat.

Authors:  Peter R Kufahl; M Foster Olive
Journal:  J Addict Res Ther       Date:  2011-11-15

Review 4.  Design, synthesis and interaction at the vesicular monoamine transporter-2 of lobeline analogs: potential pharmacotherapies for the treatment of psychostimulant abuse.

Authors:  Peter A Crooks; Guangrong Zheng; Ashish P Vartak; John P Culver; Fang Zheng; David B Horton; Linda P Dwoskin
Journal:  Curr Top Med Chem       Date:  2011       Impact factor: 3.295

5.  Nicotinic receptor ligands reduce ethanol intake by high alcohol-drinking HAD-2 rats.

Authors:  Richard L Bell; Bill J A Eiler; Jason B Cook; Shafiqur Rahman
Journal:  Alcohol       Date:  2009-12       Impact factor: 2.405

6.  Synthesis and in vitro evaluation of water-soluble 1,4-diphenethylpiperazine analogs as novel inhibitors of the vesicular monoamine transporter-2.

Authors:  Justin R Nickell; John P Culver; Venumadhav Janganati; Guangrong Zheng; Linda P Dwoskin; Peter A Crooks
Journal:  Bioorg Med Chem Lett       Date:  2016-08-02       Impact factor: 2.823

7.  Exploring the effect of N-substitution in nor-lobelane on the interaction with VMAT2: discovery of a potential clinical candidate for treatment of methamphetamine abuse.

Authors:  Guangrong Zheng; David B Horton; Narsimha Reddy Penthala; Justin R Nickell; John P Culver; Agripina G Deaciuc; Linda P Dwoskin; Peter A Crooks
Journal:  Medchemcomm       Date:  2013-03       Impact factor: 3.597

8.  Synthesis of symmetrical 1,5-disubstituted granatanines.

Authors:  Ashish P Vartak; Linda P Dwoskin; Peter A Crooks
Journal:  Tetrahedron Lett       Date:  2008-10-27       Impact factor: 2.415

9.  Sex differences in tolerance to the locomotor depressant effects of lobeline in periadolescent rats.

Authors:  Steven B Harrod; M Lee Van Horn
Journal:  Pharmacol Biochem Behav       Date:  2009-09-17       Impact factor: 3.533

10.  Human disease-drug network based on genomic expression profiles.

Authors:  Guanghui Hu; Pankaj Agarwal
Journal:  PLoS One       Date:  2009-08-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.